Literature DB >> 14760151

An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages.

R de Marco1, S Accordini, I Cerveri, A Corsico, J Sunyer, F Neukirch, N Künzli, B Leynaert, C Janson, T Gislason, P Vermeire, C Svanes, J M Anto, P Burney.   

Abstract

BACKGROUND: The recently published GOLD guidelines provide a new system for staging chronic obstructive pulmonary disease (COPD) from mild (stage I) to very severe (stage IV) and introduce a stage 0 (chronic cough and phlegm without airflow obstruction) that includes subjects "at risk" of developing the disease.
METHODS: In order to assess the prevalence of GOLD stages of COPD in high income countries and to evaluate their association with the known risk factors for airflow obstruction, data from the European Community Respiratory Health Survey on more than 18,000 young adults (20-44 years) were analysed.
RESULTS: The overall prevalence was 11.8% (95% CI 11.3 to 12.3) for stage 0, 2.5% (95% CI 2.2 to 2.7) for stage I, and 1.1% (95% CI 1.0 to 1.3) for stages II-III. Moderate to heavy smoking (> or =15 pack years) was significantly associated with both stage 0 (relative risk ratio (RRR)=4.15; 95% CI 3.55 to 4.84) and stages I+ (RRR=4.09; 95% CI 3.17 to 5.26), while subjects with stages I+ COPD had a higher likelihood of giving up smoking (RRR=1.39; 95% CI 1.04 to 1.86) than those with GOLD stage 0 (RRR=1.05; 95% CI 0.86 to 1.27). Environmental tobacco smoke had the same degree of positive association in both groups. Respiratory infections in childhood and low socioeconomic class were significantly and homogeneously associated with both groups, whereas occupational exposure was significantly associated only with stage 0. All the GOLD stages showed a significantly higher percentage of healthcare resource users than healthy subjects (p<0.001), with no difference between stage 0 and COPD.
CONCLUSIONS: A considerable percentage of young adults already suffered from COPD. GOLD stage 0 was characterised by the presence of the same risk factors as COPD and by the same high demand for medical assistance.

Entities:  

Mesh:

Year:  2004        PMID: 14760151      PMCID: PMC1746950          DOI: 10.1136/thorax.2003.011163

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  18 in total

1.  GOLD stage 0.

Authors:  Isa Cerveri; Angelo Corsico; Maria C Zoia
Journal:  Am J Respir Crit Care Med       Date:  2003-03-15       Impact factor: 21.405

2.  Nosology for our day: its application to chronic obstructive pulmonary disease.

Authors:  Gordon L Snider
Journal:  Am J Respir Crit Care Med       Date:  2003-03-01       Impact factor: 21.405

3.  The Confronting COPD International Survey: patients hardly know they have COPD.

Authors:  P N R Dekhuijzen
Journal:  Eur Respir J       Date:  2002-10       Impact factor: 16.671

4.  Physician-diagnosed asthma and drug utilization in the European Community Respiratory Health Survey.

Authors:  C Janson; S Chinn; D Jarvis; P Burney
Journal:  Eur Respir J       Date:  1997-08       Impact factor: 16.671

5.  Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease.

Authors:  Leonardo M Fabbri; Micaela Romagnoli; Lorenzo Corbetta; Gianluca Casoni; Kamelija Busljetic; Graziella Turato; Guido Ligabue; Adalberto Ciaccia; Marina Saetta; Alberto Papi
Journal:  Am J Respir Crit Care Med       Date:  2002-11-08       Impact factor: 21.405

6.  Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients.

Authors:  F De Vita; M Orditura; G Galizia; C Romano; A Roscigno; E Lieto; G Catalano
Journal:  Chest       Date:  2000-02       Impact factor: 9.410

7.  The health impact of undiagnosed airflow obstruction in a national sample of United States adults.

Authors:  D B Coultas; D Mapel; R Gagnon; E Lydick
Journal:  Am J Respir Crit Care Med       Date:  2001-08-01       Impact factor: 21.405

8.  Variations in the prevalence across countries of chronic bronchitis and smoking habits in young adults.

Authors:  I Cerveri; S Accordini; G Verlato; A Corsico; M C Zoia; L Casali; P Burney; R de Marco
Journal:  Eur Respir J       Date:  2001-07       Impact factor: 16.671

9.  Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study.

Authors:  V S Peña; M Miravitlles; R Gabriel; C A Jiménez-Ruiz; C Villasante; J F Masa; J L Viejo; L Fernández-Fau
Journal:  Chest       Date:  2000-10       Impact factor: 9.410

10.  Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease?

Authors:  Jørgen Vestbo; Peter Lange
Journal:  Am J Respir Crit Care Med       Date:  2002-08-01       Impact factor: 21.405

View more
  62 in total

1.  Early diagnosis of COPD.

Authors:  Nigel Masters; Catherine Tutt; Jenny Eades
Journal:  Br J Gen Pract       Date:  2006-12       Impact factor: 5.386

2.  Low-dose multislice CT and high-resolution CT assessment of pulmonary emphysema in public school teachers.

Authors:  Noriaki Horiuchi; Jiro Fujita; Ichizo Suemitsu; Yasuhiro Yamasaki; Futoshi Higa; Masao Tateyama
Journal:  Lung       Date:  2007-02-09       Impact factor: 2.584

3.  Deaths from chronic obstructive pulmonary disease in France, 1979-2002: a multiple cause analysis.

Authors:  C Fuhrman; E Jougla; J Nicolau; D Eilstein; M-C Delmas
Journal:  Thorax       Date:  2006-05-31       Impact factor: 9.139

Review 4.  Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema.

Authors:  Barbara A Forey; Alison J Thornton; Peter N Lee
Journal:  BMC Pulm Med       Date:  2011-06-14       Impact factor: 3.317

5.  Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: a community study.

Authors:  A Johannessen; E R Omenaas; P S Bakke; A Gulsvik
Journal:  Thorax       Date:  2005-08-05       Impact factor: 9.139

6.  Prevalence of obstructive lung disease in a general population sample: the NICECOPD study.

Authors:  Eoin Murtagh; Liam Heaney; Jenny Gingles; Richard Shepherd; Frank Kee; Chris Patterson; Joe MacMahon
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

7.  Lung function in young adults predicts airflow obstruction 20 years later.

Authors:  Ravi Kalhan; Alexander Arynchyn; Laura A Colangelo; Mark T Dransfield; Lynn B Gerald; Lewis J Smith
Journal:  Am J Med       Date:  2010-05       Impact factor: 4.965

Review 8.  Structural and functional changes of peripheral muscles in chronic obstructive pulmonary disease patients.

Authors:  Roberto A Rabinovich; Jordi Vilaró
Journal:  Curr Opin Pulm Med       Date:  2010-03       Impact factor: 3.155

9.  Dietary fiber, lung function, and chronic obstructive pulmonary disease in the atherosclerosis risk in communities study.

Authors:  Haidong Kan; June Stevens; Gerardo Heiss; Kathryn M Rose; Stephanie J London
Journal:  Am J Epidemiol       Date:  2007-12-05       Impact factor: 4.897

10.  Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and bronchodilators for severe and very severe COPD patients.

Authors:  Negro Roberto Dal; M Eandi; L Pradelli; S Iannazzo
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.